Replimune Group’s (REPL) Sell Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their sell rating on shares of Replimune Group (NASDAQ:REPL) in a report issued on Monday morning, Marketbeat Ratings reports. HC Wainwright also issued estimates for Replimune Group’s Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($3.35) EPS, Q1 2027 earnings at ($0.70) EPS, Q2 2027 earnings at ($0.68) EPS, Q3 2027 earnings at ($0.67) EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($2.71) EPS.

Other analysts also recently issued research reports about the stock. Piper Sandler downgraded shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a research report on Friday, April 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Finally, Wedbush lifted their price objective on shares of Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Six research analysts have rated the stock with a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $4.75.

Replimune Group Stock Up 16.9%

REPL stock opened at $2.28 on Monday. Replimune Group has a twelve month low of $1.50 and a twelve month high of $13.24. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $188.26 million, a P/E ratio of -0.66 and a beta of 0.74. The firm has a 50 day simple moving average of $7.21 and a 200-day simple moving average of $7.88.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.08. On average, equities research analysts predict that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of Replimune Group stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total value of $52,065.00. Following the completion of the transaction, the insider owned 151,588 shares of the company’s stock, valued at $1,214,219.88. The trade was a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds have recently added to or reduced their stakes in REPL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after purchasing an additional 6,653 shares during the period. Millennium Management LLC lifted its stake in Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after buying an additional 33,574 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after buying an additional 119,145 shares during the last quarter. Rhumbline Advisers lifted its stake in Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after buying an additional 6,616 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Replimune Group by 149.5% in the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after buying an additional 18,263 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group News Summary

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Analyst note roundup — several firms issued new/updated ratings: Leerink reaffirmed Market Perform, Jefferies reiterated Hold, and Wedbush published a Neutral. These are mostly stance-maintaining actions rather than bullish moves. Leerink Partners Reaffirms “Market Perform” Jefferies Reiterates Hold Wedbush Neutral
• Negative Sentiment: FDA rejects RP1 melanoma BLA citing trial-design concerns — the regulatory setback is the primary negative catalyst and undermines the commercial pathway/timing for RP1, prompting sharp investor selling. Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns
• Negative Sentiment: Operational impact — the company plans layoffs (63 employees) after the FDA rejection, signaling cost cuts and potential disruption to programs and morale. This amplifies downside risk to near-term execution. Mass. biotech company to lay off 63 employees after FDA rejects cancer drug for 2nd time
• Negative Sentiment: Multiple analyst downgrades and negative ratings — BMO cut to Underperform, JPMorgan to Underweight, Cantor lowered to Hold and HC Wainwright maintains a Sell. These actions increase selling pressure and reduce prospective investor demand. BMO Downgrades to Underperform JPMorgan Underweight Cantor Fitzgerald Lowers Rating HC Wainwright Reaffirms “Sell”
• Negative Sentiment: Analyst estimate cuts — HC Wainwright sharply trimmed Q1–Q4 2027 and FY2027 EPS forecasts (and lowered guidance for several quarters), reflecting expectations of greater cash burn, delayed approvals, or program setbacks; this reduces near-term valuation support. (Source: HC Wainwright research notes via market summaries)

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.